Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Bupropion · 6 trials · 5 indications
| Arm | Type | Description |
|---|---|---|
| Extended-release Bupropion Hydrochloride | OTHER | Extended-release Bupropion Hydrochloride |
| Name | Type | Description |
|---|---|---|
| Extended-release bupropion (HCl) | DRUG | - |
| Extended-Release Bupropion Hydrochloride | DRUG | - |
Inclusion criteria: * Primary diagnosis of MDD with current duration lasting 12 weeks but no greater than 2 years. * Generally in good health. * Subject must read and write at a level sufficient to provide written informed consent. Exclusion criteria: * Current or past history of seizure disorder...
Top 20 of 29 competitors
Bupropion is an investigational small molecule being studied for psychiatric and neurological conditions, including Attention Deficit Disorder, Epilepsy, Major Depressive Disorder (MDD), Seasonal Affective Disorder, and Depressive Disorder. It is being developed by GSK plc (GSK) and is currently in Phase 1 clinical development.
Bupropion is being developed by GSK plc, a pharmaceutical company traded under the ticker GSK. The drug is currently in Phase 1 clinical development for multiple psychiatric indications, including Major Depressive Disorder and Seasonal Affective Disorder.
Bupropion is in Phase 1 clinical development. It has completed a total of two clinical trials, both of which are finished, with no active trials currently ongoing. The drug is investigational and has not been approved by regulatory authorities.
Bupropion has been studied in two completed clinical trials. One trial, NCT00046241, investigated prevention of Seasonal Affective Disorder with 300 participants. Another trial, NCT00048360, studied Attention-Deficit Hyperactivity Disorder in adults with 162 participants. Both trials were completed in the United States and Canada.
Bupropion is the drug name used in clinical trials for this investigational compound. No alternative names have been established for this drug in the available clinical trial data. It is being studied under the name Bupropion across all listed trials.